My NCBISign In
Drotrecogin alfa (activated): real-life use and outcomes for the UK
Kathryn M Rowan, Catherine A Welch, Emma North, David A Harrison
Crit Care. 2008; 12(2): R58. Published online 2008 April 22. doi: 10.1186/cc6879
PMCID:
PMC2447613
Abstract Full Text PDF–348K Supplementary Material

Is Cited by the Following 4 Articles in this Archive:

Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
M Zia Sadique, Richard Grieve, David A Harrison, Brian H Cuthbertson, Kathryn M Rowan
Crit Care. 2011; 15(5): R228. Published online 2011 September 26. doi: 10.1186/cc10468
PMCID:
PMC3334774
Abstract Full Text PDF–372K Supplementary Material
Drotrecogin alfa (activated): a single-centre experience of 110 patients
S Fletcher, N Pathmanathan
Crit Care. 2010; 14(Suppl 1): P407. Published online 2010 March 1. doi: 10.1186/cc8639
PMCID:
PMC2934176
Full Text PDF–7.4M
Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies
Laith Altaweel, Daniel Sweeney, Xizhong Cui, Amisha Barochia, Charles Natanson, Peter Q Eichacker
Biologics. 2009; 3: 391–406. Published online 2009 September 15.
PMCID:
PMC2747338
Abstract Full Text PDF–439K
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
Greg Martin, Frank M Brunkhorst, Jonathan M Janes, Konrad Reinhart, David P Sundin, Kassandra Garnett, Richard Beale
Crit Care. 2009; 13(3): R103. Published online 2009 June 30. doi: 10.1186/cc7936
PMCID:
PMC2717475
Abstract Full Text PDF–233K Supplementary Material
You are here: NCBI > Literature > PubMed Central (PMC)
Write to the Help Desk